Clinical Trial Update: Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 [Phase 2]

View source ↗

Summary

Phase 2 trial of ipilimumab in patients with advanced/metastatic melanoma and spontaneous preexisting NY-ESO-1 immune response has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: National Center for Tumor Diseases, Heidelberg | Conditions: Metastatic Melanoma | Phase 2 | Status: COMPLETED